
The FDA will review a new drug application for the oral agent uridine triacetate as a treatment for patients at risk of serious toxicity following an overdose of 5-fluorouracil (5-FU) or are exhibiting symptoms of serious toxicity within 96 hours of 5-FU administration.


















